FMT

The human gut is a complex microbial ecosystem comprising approximately 100 trillion microbes collectively known as the "gut microbiota". At a rough estimate, the human gut microbiome contains almost 3.3 million genes, which are about 150 times more than the total human genes present in the human ge …

Innovation Fund Denmark.

👍 from @FDA: An advisory board recommended the agency approve a fecal microbiota transfer (FMT) product for recurrent #Cdiff infections. Committee members swayed by strong "need" rather than strong data: https://t.co/TXSej2hp22 #IDTwitter #GITwitter @ingridhein @medpagetoday— MedPage Infectious Disease (@MedPageID) September 24, 2022

Real-world data showed no difference in cure rates at 1 and 2 months

Fecal microbiota transplantation (FMT) is one of the recommended treatments for recurrent Clostridioides difficile infection, but endoscopy and available oral formulations still have several limitations in their preparation, storage, and administration. The need for a viable oral formulation that facilitates the implementation of this highly effective therapy in different settings has led us to test the microcrystalline cellulose particles as an adsorbent of concentrated filtered fresh feces in comparison to lyophilized feces. This free-flowing material can provide protection to bacteria and results in a dried product able to maintain the viability of the microbiota for a long time. Adsorbate formulation showed a stabilizing effect in gut microbiota, maintaining bacteria viability and preserving its diversity, and is a competitive option for lyophilized capsules.

Minnesota: In a prospective trial published in the Journal of Clinical Gastroenterology and Hepatology, fecal microbiota transplantation (FMT) administered through oral capsule or colonic...

In patients with first or second C difficile infection, first-line faecal microbiota transplantation is highly effective and superior to the standard of care vancomycin alone in achieving sustained resolution from C difficile.

Committee members swayed by strong 'need' rather than strong data

The clinical development program for RBX2660 included 6 studies with a total of 1061 patients, of which 978 were treated with RBX2660.

Committee members voted in support of Rebiotix’s treatment for recurrent C. diff infections of the intestines, a condition with no approved options after antibiotics fail.

A panel of U.S. Food and Drug Administration advisers voted in favor of Ferring Pharmaceuticals' fecal transplant-based therapy to reduce the recurrence of a bacterial infection, bringing the first therapy of its kind closer to approval.

A panel of U.S. Food and Drug Administration advisers voted in favor of Ferring Pharmaceuticals' fecal transplant-based therapy to reduce the recurrence of a bacterial infection, bringing the first therapy of its kind closer to approval.

In patients with first or second C difficile infection, first-line faecal microbiota transplantation is highly effective and superior to the standard of care vancomycin alone in achieving sustained resolution from C difficile.

Fecal microbiota transplantation delivered via capsule is as effective as endoscopically delivered #FMT to prevent recurrent C. difficile.Older age, hemodialysis, and post-FMT antibiotics 🔗 with ⬇️ cure rates.#MedTwitter #GITwitter #Cdiff #microbiomehttps://t.co/0K69yeNGIh— John Damianos, M.D. (@john_damianosMD) September 21, 2022

Understanding the factors underlying colonization of donor microbes in recipients of fecal #microbiota transplantation is a necessary first step to develop directed approaches to couple colonization to clinical outcomes. #FMT https://t.co/TNFCx5O9CU— Nature Medicine (@NatureMedicine) September 19, 2022

Sprawling data set, an imbalance in deaths, and posterior probabilities to be discussed

Looking forward to questions from ppl on @Reddit @RedditAskSci . There are a lot of interesting things to discuss as we still understand #microbiome dynamics post #FMT only very incompletely./end— Sebastian Schmidt (@TSBSchm) September 21, 2022

Drs Tom Lodise and Bincy Abraham provide an overview of fecal microbiota transplantation and long-term safety of FMT use.

Background and Aims Fecal microbiota transfer (FMT) is a potential treatment for irritable bowel syndrome (IBS). Several randomized trials have tested FMT effects using different routes of administr...

Fecal microbiota transplantation (FMT) has shown promising results in animal models of obesity, while results in human studies are inconsistent. We ai…

I remember the "excitement" years ago surrounding #FMT as a tx. modality for #IBD #crohns, but it fizzled out. Now more precise info is emerging thanks to high quality research like this. Right donor profile + specific targets could highly personalize this. https://t.co/XLDnTtlUNH— Natalie RDH BHA (@DHadvocate1) September 20, 2022

Cap-FMT using freeze dried capsules has a similar safety and effectiveness profile compared to colo-FMT, without the procedural risks of colonoscopy. While highly effective overall, patient selection is a key factor to optimizing FMT success.

“Novel technologies to characterize & engineer the microbiome in IBD” via @tandfonline. Therapies patients can be on the lookout for:👉 #FMT👉 Engineered microbes 👉 #Phage therapy👉 Microbial metabolite therapy👉 Defined microbial consortiahttps://t.co/rCPNvCvwq8 pic.twitter.com/hKdvWZlNFr— IBD Patient Voice 🙋‍♀️ (@IBDPatientVoice) September 19, 2022

Fecal microbiota transplantation (FMT) has shown promising results in animal models of obesity, while results in human studies are inconsistent. We ai…

Compared to fidaxomicin and vancomycinfecal, microbiota transplant (FMT) was the most cost-effective treatment for first and subsequent recurrent C difficile infection.

Correcting the altered gut microbiome is an important goal in Clostridioides difficile management, but the matter is not addressed by mainstream treatments with antibiotics. This article focuses on where fecal microbiota transplantation and investigational microbiota-based therapeutics stand for C. difficile infection (Part 3)

Important #FMT studies advancing our current knowledge! Species specific engraftment patterns, pretreatment and application method. Microbiome interventions refined to specific disease entities may be the next big step! https://t.co/Dp9EfVgSpw— Simon MD Baunwall (@SMDBaunwall) September 17, 2022